Stem Cell Policy and Ethics Program

The Stem Cell Policy and Ethics Program (SCOPE) was first conceptualized early in 2002 as a formal and ongoing conduit for collaboration between faculty and staff of the Johns Hopkins Berman Institute of Bioethics and the Johns Hopkins Institute for Cell Engineering. SCOPE is designed to address the increasing importance, in both the conduct of research and the development of clinical applications, of interactions between the fields of stem cell science, ethics, and public policy.

Mission Statement

The SCOPE (formerly known as the Program in Cell Engineering, Ethics, and Public Policy – PCEEPP) program’s mission is to:

  • Facilitate the ability of the public to benefit from advances in cell engineering in morally responsible ways.
  • Anticipate moral and policy challenges in stem cell science and cell engineering
  • Provide opportunity for careful and interdisciplinary analysis of these challenges that will be of assistance to both policymakers and the public.

Helpful Links

How do we deal with the ethical and safety issues around human stem cell research and therapy?
The Promise of Stem Cell Research
Stem Cell Ethics: A Proactive Approach
Are Induced Pluripotent Stem Cells Safe Yet?


Science, Ethics and Policy Challenges of Pluripotent Stem Cell-derived Gametes
The Working Group on Human Trials of Cell-Based Interventions for Neurological Conditions
Transnational Cooperation in Stem Cell Research
The Working Group on the Criteria for Cell-Based Therapies


  • Duggan, P.S., Siegel, A.W., Bok, H., et al. (2009). Unintended Changes in Cognition, Mood, and Behavior Arising from Cell-Based Interventions for Neurological Conditions: Ethical Challenges. Am J Bioethics Neurosci, The American Journal of Bioethics, 9(5), 31–36.
  • Regenberg, A., Mathews, D.J., Blass, D.M., et al. (2009). The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. J Cereb Blood Flow Metab [Epub ahead of print], 29, 1-9
  • Mathews, D.J.H., Sugarman, J., Bok, H., et al. (2008). Cell-Based interventions for neurological conditions: Ethical challenges for early human trials. Neurology, 71, 288-93.
  • Consensus statement of the Hinxton Group (April 11, 2008): Science, Ethics and Policy Challenges of Pluripotent Stem Celll-Derived Gametes
  • Faden, R., (2006). The road to balanced oversight. Science August 18;313(5789):891
  • Mathews, D.J., Donovan, P., Harris, J., Lovell-Badge, R., Savulescu, J., Faden, R. Science and law. Integrity in international stem cell research collaborations. Science 2006 August 18;313(5789):921-2.
  • Consensus statement of the Hinxton Group (February 24, 2006): Transnational Cooperation in Stem Cell Research
  • Savulescu J, Saunders R. The “Hinxton Group” considers transnational stem cell research. Hastings Cent Rep 2006 May;36(3):1.
  • Greene M, Schill K, Takahashi S et al. Ethics: Moral issues of human-non-human primate neural grafting. Science 2005 July 15;309(5733):385-6.
  • Bok, H., Schill, K.E., Faden, R.R. Justice, ethnicity, and stem-cell banks. Lancet 2004 July 10;364(9429):118-21.
  • Dawson, L., Bateman-House, A.S., Mueller, A.D. et al. Safety issues in cell-based intervention trials. Fertil Steril 2003 November;80(5):1077-85.
  • Faden, R.R., Dawson, L., Bateman-House, A.S. et al. Public stem cell banks: considerations of justice in stem cell research and therapy. Hastings Cent Rep 2003 November;33(6):13-27.
  • Siege,l A.W. The moral insignificance of crossing species boundaries. Am J Bioeth 2003;3(3):33-4.
  • Mathews, D.J., Donovan, P., Harris, J., Lovell-Badge, R., Savulescu, J., Faden, R. Pluripotent stem cell derived gametes: truth and (potential) consequences.Cell Stem Cell 2009 July 2;5(1):11-14.
  • Regenberg, A.C., Hutchinson, L.A., Schanker, B., Mathews, D.J.H. Medicine on the fringe: stem-cell interventions in advance of evidence. Stem cells [published online May 21, 2009]
  • Sugarman, J. & Siegel, A. When embryonic stem cell lines fail to meet consent standards. Science 2008; 322(5900):379.
  • Sugarman J & Siegel A. How to determine whether existing human embryonic stem cell lines can be used ethically.Cell Stem Cell 2008; 3(3): 238-9.


  • Ruth Faden, Ph.D., M.P.H. — Philip Franklin Wagley Professor of Biomedical Ethics; Director, Johns Hopkins Berman Institute of Bioethics
  • Debra Mathews, Ph.D. — Assistant Director for Science Programs, Johns Hopkins Berman Institute of Bioethics Assistant Professor, Department of Pediatrics
  • Alan Regenberg, M. Be. — Director of Outreach and Research Support, Johns Hopkins Berman Institute of Bioethics
  • Hilary Bok, Ph.D. — Henry R. Luce Professor of Bioethics and Moral and Political Theory, Department of Philosophy; Core Faculty, Berman Institute
  • Linzhao Cheng, Ph.D. — Associate Professor, Stem Cell Program Institute for Cell Engineering
  • Jennifer Elisseeff, Ph.D. — Assistant Professor, Department of Biomedical Engineering
  • Andrew Siegel, Ph.D., J.D. — Assistant Professor, Department of Gynecology-Obstetrics; Core Faculty, Berman Institute of Bioethics
  • Hongjun Song, Ph.D. — Assistant Professor, Institute For Cell Engineering
  • Jeremy Sugarman, M.D., M.P.H., M.A. — Harvey M. Meyerhoff Professor of Bioethics & Medicine; Deputy Director for Medicine, Berman Institute of Bioethics
  • Elias Zambidis, M.D., Ph.D. — Assistant Professor, Johns Hopkins University, School of Medicine


Alan Regenberg
SCOPE Program Coordinator
1809 Ashland Ave.
Baltimore, MD 21205